Topic

Pharmaceutical M&A

Acquisitions of biotech companies by large drugmakers, usually priced on the expected value of clinical-stage assets.

Current clusters

science2 publishers

One missed hand-opening endpoint costs Novartis 2.5 times the Avidity purchase price

Artisan Partners' David Samra is telling Novartis's chairman to rebuild the team that does its deals, after a week of three Phase III setbacks in which one of the drugs actually met its primary endpoint.

Publishers:genengnews.comstatnews.com

Reality

Evidence66
Adoption22
Hype gap+28
Incentives68
Confidence62